Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong.
Department of Clinical Oncology, The Chinese University of Hong Kong, New Territories, Hong Kong.
Asia Pac J Clin Oncol. 2021 Apr;17 Suppl 3:12-26. doi: 10.1111/ajco.13580.
To update the Hong Kong Urological Association-Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer, the same panelists as in the previous consensus panel held a series of meetings to discuss updated clinical evidence and experiences.
The previous consensus statements were retained, deleted, or revised, and new statements were added. At the final meeting, all statements were reviewed and amended as appropriate, followed by panel voting.
There were significant changes and additions to the previous consensus statements, primarily driven by the advances in androgen receptor signaling inhibitors, treatment sequencing in metastatic castration-resistant prostate cancer, and increasing recognition of oligometastatic prostate cancer since the introduction of prostate-specific membrane antigen positron emission tomography. In this update, a total of 59 consensus statements were accepted and established.
The consensus panel updated consensus statements on the management of advanced prostate cancer, aiming to allow physicians in the region to keep abreast of the recent evidence on optimal clinical practices.
为更新香港泌尿科协会-香港泌尿肿瘤学会关于晚期前列腺癌管理的共识声明，与前一次共识小组会议相同的小组成员举行了一系列会议，讨论更新的临床证据和经验。
保留、删除或修改了以前的共识声明，并添加了新的声明。在最后一次会议上，对所有声明进行了审查和适当的修订，随后进行了小组投票。
与以前的共识声明相比，有了重大的变化和补充，主要是由于雄激素受体信号抑制剂的进展、转移性去势抵抗性前列腺癌的治疗顺序以及自从前列腺特异性膜抗原正电子发射断层扫描（prostate-specific membrane antigen positron emission tomography）引入以来对寡转移前列腺癌的认识不断提高。在本次更新中，共接受并确立了 59 项共识声明。
共识小组更新了关于晚期前列腺癌管理的共识声明，旨在使该地区的医生能够跟上最佳临床实践的最新证据。
